Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cytokines
Biotech
ESMO: Innovent links cytokine to colorectal cancer responses
A phase 1 that combined the candidate with bevacizumab reported a 21.9% response rate, including efficacy in patients with prior immunotherapy use.
Nick Paul Taylor
Sep 18, 2024 9:53am
Innovent links IL-2 fusion protein to responses in small study
Jun 14, 2024 10:00am
AACR: Mural debuts data for potential pipeline additions
Apr 10, 2024 11:16am
Gilead pays $43.5M for Xilio's early-phase IL-12 prospect
Mar 28, 2024 8:08am
Sanofi pays $40M to join preclinical push against vexing target
Jan 29, 2024 8:00am
Oncternal reports patient death in CAR-T dose-escalation study
Dec 28, 2023 10:52am